Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Pierce

Showing results (881-890 of 988) with videos related to

Pageof 99
Sort By:
Molecular Cancer Therapeutics|May 8, 2015
A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated PathwaysJonathan Rios-Doria, Darrin Sabol, Jon Chesebrough, et al.
Scientific Reports|August 11, 2022
Distribution and genetic diversity of Anisakis spp. in cetaceans from the Northeast Atlantic Ocean and the Mediterranean SeaPaolo Cipriani, Marialetizia Palomba, Lucilla Giulietti, et al.
British Journal of Cancer|January 25, 2023
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancerGiuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2008
SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumoniaPatrick G P Charles, Rory Wolfe, Michael Whitby, et al.
British Journal of Cancer|November 6, 2022
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancerGiuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, et al.
Practical Radiation Oncology|November 17, 2023
Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice GuidelineSimona F Shaitelman, Bethany M Anderson, Douglas W Arthur, et al.
Molecular Cancer Therapeutics|March 17, 2018
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion ProteinMichael D Oberst, Catherine Augé, Chad Morris, et al.
NPJ Breast Cancer|February 24, 2026
Transcriptomic analysis to uncover the mechanism of radiosensitization of AR-positive triple-negative breast cancers with AR inhibitionBreanna McBean, Benjamin Hauk, Anna R Michmerhuizen, et al.
Practical Radiation Oncology|November 20, 2023
Publisher's Note to Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline (Pract Radiat Oncol. 2024;14:xxx-xxx. Epub ahead of print November 14, 2023.)Simona F Shaitelman, Bethany M Anderson, Douglas W Arthur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2021
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804Beryl McCormick, Kathryn A Winter, Wendy Woodward, et al.
Pageof 99

Showing results (881-890 of 988) with videos related to

Sort By:
Pageof 99
Molecular Cancer Therapeutics|May 8, 2015
A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated PathwaysJonathan Rios-Doria, Darrin Sabol, Jon Chesebrough, et al.
Scientific Reports|August 11, 2022
Distribution and genetic diversity of Anisakis spp. in cetaceans from the Northeast Atlantic Ocean and the Mediterranean SeaPaolo Cipriani, Marialetizia Palomba, Lucilla Giulietti, et al.
British Journal of Cancer|January 25, 2023
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancerGiuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2008
SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumoniaPatrick G P Charles, Rory Wolfe, Michael Whitby, et al.
British Journal of Cancer|November 6, 2022
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancerGiuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, et al.
Practical Radiation Oncology|November 17, 2023
Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice GuidelineSimona F Shaitelman, Bethany M Anderson, Douglas W Arthur, et al.
Molecular Cancer Therapeutics|March 17, 2018
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion ProteinMichael D Oberst, Catherine Augé, Chad Morris, et al.
NPJ Breast Cancer|February 24, 2026
Transcriptomic analysis to uncover the mechanism of radiosensitization of AR-positive triple-negative breast cancers with AR inhibitionBreanna McBean, Benjamin Hauk, Anna R Michmerhuizen, et al.
Practical Radiation Oncology|November 20, 2023
Publisher's Note to Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline (Pract Radiat Oncol. 2024;14:xxx-xxx. Epub ahead of print November 14, 2023.)Simona F Shaitelman, Bethany M Anderson, Douglas W Arthur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2021
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804Beryl McCormick, Kathryn A Winter, Wendy Woodward, et al.
Pageof 99